Bradford T. Whitmore Buys 444,444 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc. (NASDAQ:CLSDGet Free Report) major shareholder Bradford T. Whitmore bought 444,444 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average price of $1.35 per share, with a total value of $599,999.40. Following the transaction, the insider now directly owns 4,495,034 shares of the company’s stock, valued at approximately $6,068,295.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Clearside Biomedical Price Performance

NASDAQ:CLSD opened at $1.42 on Monday. The firm has a market capitalization of $88.62 million, a price-to-earnings ratio of -2.33 and a beta of 2.30. The business has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $1.04. Clearside Biomedical, Inc. has a 1 year low of $0.65 and a 1 year high of $1.54.

Clearside Biomedical (NASDAQ:CLSDGet Free Report) last announced its earnings results on Monday, November 13th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Clearside Biomedical had a negative return on equity of 533.87% and a negative net margin of 1,687.74%. The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $0.22 million. During the same quarter in the previous year, the business earned ($0.13) EPS. As a group, analysts expect that Clearside Biomedical, Inc. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CLSD shares. upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research report on Tuesday, November 14th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Clearside Biomedical currently has an average rating of “Moderate Buy” and an average target price of $5.00.

View Our Latest Stock Report on CLSD

Institutional Investors Weigh In On Clearside Biomedical

Institutional investors and hedge funds have recently modified their holdings of the business. Balyasny Asset Management LLC bought a new stake in shares of Clearside Biomedical during the 3rd quarter worth approximately $25,000. Mackenzie Financial Corp bought a new position in shares of Clearside Biomedical in the 1st quarter worth $27,000. JPMorgan Chase & Co. raised its position in shares of Clearside Biomedical by 100.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,161 shares of the company’s stock worth $27,000 after acquiring an additional 9,109 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of Clearside Biomedical in the 2nd quarter worth $35,000. Finally, Virtu Financial LLC bought a new position in shares of Clearside Biomedical in the 2nd quarter worth $38,000. 13.70% of the stock is owned by institutional investors.

About Clearside Biomedical

(Get Free Report)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.

Featured Stories

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with's FREE daily email newsletter.